{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:55:51Z","timestamp":1783047351084,"version":"3.54.6"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":226,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NeuroImage: Clinical"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.nicl.2023.103497","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:56:54Z","timestamp":1692100614000},"page":"103497","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Multimodal imaging study of the 5-HT1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5874-6858","authenticated-orcid":false,"given":"Sarah","family":"Chaib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bouillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Depoortere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2805-7098","authenticated-orcid":false,"given":"Luc","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Levigoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nicl.2023.103497_b0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp.74.4.419","article-title":"Occipital hypoperfusion in Parkinson\u2019s disease without dementia: correlation to impaired cortical visual processing","volume":"74","author":"Abe","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.nicl.2023.103497_b0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00702-003-0094-7","article-title":"Sarizotan, a serotonin 5-HT 1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile","volume":"111","author":"Bartoszyk","year":"2004","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.nicl.2023.103497_b0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2015.07.002","article-title":"Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson\u2019s disease","volume":"132","author":"Bastide","year":"2015","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nicl.2023.103497_b0020","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nicl.2023.103497_b0025","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.nicl.2023.103497_b0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/jnr.21978","article-title":"Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats","volume":"87","author":"Bishop","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nicl.2023.103497_b0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.nicl.2023.103497_b0040","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0045","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0050","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.27337","article-title":"Animal models of l-dopa-induced dyskinesia in Parkinson\u2019s disease","volume":"33","author":"Cenci","year":"2018","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.nicl.2023.103497_b0055","first-page":"Unit 9.25","article-title":"Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson\u2019s disease in rats and mice","volume":"9","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci. Chapter"},{"key":"10.1016\/j.nicl.2023.103497_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.parkreldis.2012.06.003","article-title":"Prefrontal thickening in PD with levodopa-induced dyskinesias: new evidence from cortical thickness measurement","volume":"19","author":"Cerasa","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2023.103497_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11910-016-0687-9","article-title":"Connectivity Changes in Parkinson\u2019s Disease","volume":"16","author":"Cerasa","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.nicl.2023.103497_b0070","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nicl.2023.103497_b0075","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson\u2019s disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0080","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques","volume":"78","author":"Depoortere","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.nicl.2023.103497_b0090","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/jcbfm.1994.99","article-title":"The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab","volume":"14","author":"Eidelberg","year":"1994","journal-title":"Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nicl.2023.103497_b0095","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.nicl.2023.103497_b0100","first-page":"268","article-title":"Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review","volume":"19","author":"Farajdokht","year":"2020","journal-title":"EXCLI J."},{"key":"10.1016\/j.nicl.2023.103497_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"issue":"118","key":"10.1016\/j.nicl.2023.103497_b0110","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00702-010-0571-8","article-title":"Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease","volume":"1996","author":"Gerlach","year":"2011","journal-title":"J. Neural Transm. Vienna Austria"},{"key":"10.1016\/j.nicl.2023.103497_b0115","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s004150050530","article-title":"Risk factors for levodopa-induced dyskinesias in Parkinson\u2019s disease","volume":"246","author":"Grandas","year":"1999","journal-title":"J. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.nicl.2023.103497_b0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/mds.26540","article-title":"Resting-state connectivity predicts levodopa-induced dyskinesias in Parkinson\u2019s disease","volume":"31","author":"Herz","year":"2016","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.nicl.2023.103497_b0130","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(93)90576-9","article-title":"Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats","volume":"626","author":"Hudson","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.nicl.2023.103497_b0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/nmt-2018-0017","article-title":"5-HT1A agonists and dyskinesia in Parkinson\u2019s disease: a pharmacological perspective","volume":"8","author":"Huot","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.nicl.2023.103497_b0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1021\/acschemneuro.6b00440","article-title":"Serotonergic Approaches in Parkinson\u2019s Disease: Translational Perspectives, an Update","volume":"8","author":"Huot","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.nicl.2023.103497_b0145","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.neuropharm.2006.05.030","article-title":"The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors","volume":"51","author":"Kuzhikandathil","year":"2006","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.nicl.2023.103497_b0155","doi-asserted-by":"crossref","first-page":"e109113","DOI":"10.1371\/journal.pone.0109113","article-title":"A multi-atlas based method for automated anatomical rat brain MRI segmentation and extraction of PET activity","volume":"9","author":"Lancelot","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nicl.2023.103497_b0160","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(77)92939-7","article-title":"\u201cOff period\u201d dystonia and \u201con period\u201d choreoathetosis in levodopa-treated patients with Parkinson\u2019s disease","volume":"2","author":"Lees","year":"1977","journal-title":"Lancet Lond. Engl."},{"issue":"9680","key":"10.1016\/j.nicl.2023.103497_b0165","first-page":"2055","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Parkinson\u2019s disease. Lancet Lond. Engl."},{"key":"10.1016\/j.nicl.2023.103497_b0170","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00584","article-title":"Serotonin 5-HT 1A Receptor Biased Agonists Induce Different Cerebral Metabolic Responses: A [18 F]-Fluorodesoxyglucose Positron Emission Tomography Study in Conscious and Anesthetized Rats","volume":"10","author":"Levigoureux","year":"2019","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.nicl.2023.103497_b0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00213-011-2569-9","article-title":"In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat","volume":"221","author":"Llad\u00f3-Pelfort","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.nicl.2023.103497_b0180","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.jcbfm.9600358","article-title":"Abnormal metabolic network activity in Parkinson\u2019s disease: test-retest reproducibility. J. Cereb. Blood Flow Metab","volume":"27","author":"Ma","year":"2007","journal-title":"Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.nicl.2023.103497_b0185","first-page":"196","article-title":"Increased affinity of dopamine for D(2) -like versus D(1) -like receptors. Relevance for volume transmission in interpreting PET findings","volume":"66","author":"Marcellino","year":"2012","journal-title":"Synap. N. Y. N"},{"key":"10.1016\/j.nicl.2023.103497_b0190","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(77)91146-1","article-title":"Success and problems of long-term levodopa therapy in Parkinson\u2019s disease","volume":"1","author":"Marsden","year":"1977","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.nicl.2023.103497_b0195","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","article-title":"The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements","volume":"105","author":"McCreary","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nicl.2023.103497_b0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12311-018-0981-y","article-title":"Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson\u2019s Disease","volume":"18","author":"Mueller","year":"2019","journal-title":"Cerebellum Lond. Engl."},{"key":"10.1016\/j.nicl.2023.103497_b0205","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Mu\u00f1oz","year":"2008","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0210","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Mu\u00f1oz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0215","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.neuroimage.2010.09.028","article-title":"Parkinson\u2019s disease tremor-related metabolic network: characterization, progression, and treatment effects","volume":"54","author":"Mure","year":"2011","journal-title":"Neuroimage"},{"key":"10.1016\/j.nicl.2023.103497_b0220","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/jphp.12762","article-title":"Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist","volume":"69","author":"Newman-Tancredi","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.nicl.2023.103497_b0225","doi-asserted-by":"crossref","first-page":"107937","DOI":"10.1016\/j.pharmthera.2021.107937","article-title":"Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders","volume":"229","author":"Newman-Tancredi","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.nicl.2023.103497_b0230","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1038\/s41598-020-68514-0","article-title":"Shared functional neural substrates in Parkinson\u2019s disease and drug-induced parkinsonism: association with dopaminergic depletion","volume":"10","author":"Oh","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nicl.2023.103497_b0235","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1248\/bpb.b13-00310","article-title":"Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions","volume":"36","author":"Ohno","year":"2013","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.nicl.2023.103497_b0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.irn.2018.08.002","article-title":"Molecular Imaging of the Serotonergic System in Parkinson\u2019s Disease","volume":"141","author":"Pagano","year":"2018","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.nicl.2023.103497_b0245","series-title":"The rat brain in stereotaxic coordinates","author":"Paxinos","year":"2014"},{"issue":"9","key":"10.1016\/j.nicl.2023.103497_b0250","doi-asserted-by":"crossref","first-page":"e0202597","DOI":"10.1371\/journal.pone.0202597","article-title":"Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson\u2019s disease evaluated with multimodal MRI","volume":"13","author":"Perlbarg","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.nicl.2023.103497_b0255","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primer"},{"key":"10.1016\/j.nicl.2023.103497_b0260","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nicl.2023.103497_b0265","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nicl.2023.103497_b0270","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.nicl.2023.103497_b0275","first-page":"637","article-title":"Functional Connectivity Signatures of Parkinson\u2019s Disease","volume":"9","author":"Tessitore","year":"2019","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.nicl.2023.103497_b0280","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/s41386-018-0145-2","article-title":"In vivo biased agonism at 5-HT1A receptors: characterisation by simultaneous PET\/MR imaging","volume":"43","author":"Vidal","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nicl.2023.103497_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107867","article-title":"Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists","volume":"172","author":"Vidal","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.nicl.2023.103497_b0290","first-page":"1257","article-title":"Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson\u2019s Disease and Levodopa-Induced Dyskinesia: A microPET Study","volume":"11","author":"Vidal","year":"2021","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.nicl.2023.103497_b0295","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/nm.3290","article-title":"Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales","volume":"19","author":"Wehrl","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.nicl.2023.103497_b0300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2003.tb07477.x","article-title":"Pathophysiology of Parkinson\u2019s Disease: The MPTP Primate Model of the Human Disorder","volume":"991","author":"Wichmann","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["NeuroImage: Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158223001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213158223001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:45:55Z","timestamp":1761972355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213158223001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":60,"alternative-id":["S2213158223001882"],"URL":"https:\/\/doi.org\/10.1016\/j.nicl.2023.103497","relation":{},"ISSN":["2213-1582"],"issn-type":[{"value":"2213-1582","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal imaging study of the 5-HT1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia","name":"articletitle","label":"Article Title"},{"value":"NeuroImage: Clinical","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nicl.2023.103497","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103497"}}